Watchlist Price Alert

Arbutus Biopharma Corpora... (ABUS)

NASDAQ: ABUS · Real-Time Price · USD

3.08

-0.04 (-1.28%)

At close: May 16, 2025, 3:59 PM

3.22

4.38%

After-hours: May 16, 2025, 04:45 PM EDT

-1.28% (1D)

Bid	3.09
Market Cap	590.86M
Revenue (ttm)	6.4M
Net Income (ttm)	-76.57M
EPS (ttm)	-0.38
PE Ratio (ttm)	-8.12
Forward PE	-31.2
Analyst	Buy

Ask	3.26
Volume	806,215
Avg. Volume (20D)	1,071,420
Open	3.07
Previous Close	3.12
Day's Range	3.05 - 3.15
52-Week Range	2.71 - 4.72
Beta	1.50

About ABUS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ABUS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ABUS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Arbutus Biopharma has released their quartely earnings on May 14, 2025:

Revenue of $1.76M misses estimates by $526K, with 15.14% YoY growth.

EPS of -0.13 exceeds estimates by 0.02, with -30.00% YoY decline.

Why Price Moved

1 week ago

-0.9%

ABUS stock has given up its prior gain. Arbutus Bi... Unlock content with Pro Subscription

1 week ago

-0.9%

Arbutus Biopharma shares are trading higher after the company presented clinical trial data from its two HBV assets.

News

3 days ago · zacks.com

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago.

3 weeks ago · zacks.com

Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know

Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago · zacks.com

All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy

Arbutus (ABUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago · zacks.com

Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?

Here is how Arbutus Biopharma (ABUS) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

1 month ago · zacks.com

Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.12 per share a year ago.

1 month ago · businesswire.com

GE HealthCare launches AI-driven, patient-friendly Invenia ABUS Premium to accelerate scanning and drive early cancer detection in dense breasts

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) announced the launch of Invenia™ Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound offering advanced artificial intelligence (...